Pericardial Effusion Associated with Left Ventricle Hypertrophy and Macrophage Activation Syndrome Revealing Systemic Lupus Erythematosus: A Case Report
Published: 2023-02-15
Page: 52-55
Issue: 2023 - Volume 6 [Issue 1]
Haless Kamal *
Cardiology Intensive Care Unit, Chu Ibn Rochd of Casablanca, Morocco.
Yamoul Jihan
Cardiology Intensive Care Unit, Chu Ibn Rochd of Casablanca, Morocco.
El Aiassi Anas
Cardiology Intensive Care Unit, Chu Ibn Rochd of Casablanca, Morocco.
Habbal Rachida
Cardiology Intensive Care Unit, Chu Ibn Rochd of Casablanca, Morocco.
Leila Azzouzi
Cardiology Intensive Care Unit, Chu Ibn Rochd of Casablanca, Morocco.
Abdenasser Drighil
Cardiology Intensive Care Unit, Chu Ibn Rochd of Casablanca, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Introduction: Systemic lupus erythematosus is an autoimmune disease of unknown etiology. Despite the rarity of clinical manifestations, cardiac involvement is one of the major causes of mortality.
Case Presentation: We report the case of a patient with severe pericardial effusion and concentric left ventricle hypertrophy (LVH) in whom lupus was manifested by macrophage activation syndrome. she was admitted to the emergence department for fever, chest pain and progressive dyspnea. She also reports having developed inflammatory polyarthralgia for 1 year. Cardiomegaly was noted on chest radiograph. The ECG showed microvoltage and sinus tachycardia. The echocardiography showed a severe pericardial effusion with diastolic collapse of the right ventricle and respiratory variations. Faced with this brutal scenario (pre- tamponade), the patient underwent pericardiocentesis with extraction of 900cc of citrine-yellow exudative fluid. A macrophage activation syndrome test was carried out coming back positive. The diagnosis of systemic lupus erythematosus complicated by macrophage activation syndrome was retained (according to the ACR/EULAR 2019 criteria). The patient was treated by corticotherapy. The evolution was favorable with disappearance of the pericardial effusion. This therapy prevents recurrence of symptoms.
Discussion: Cardiovascular manifestations of systemic lupus erythematosus may involve all heart structure specially pericardium, valve, conduction system and coronary arteries. Pericardial involvement is the first to occur in 11% to 54% of cases according to some studies. Patients with systemic lupus erythematosus have an increased prevalence of left ventricle hypertrophy. The studies suggest that inflammation-mediated arterial stiffening is likely to be the underlying mechanism of left ventricle hypertrophy in systemic lupus erythematosus. Thus, the occurrence of macrophage activation syndrome at the same time as lupus appears to be a rare but seems to define a severe form of systemic lupus erythematosus. Early therapy with high-dose intravenous corticosteroids is usually used in macrophage activation syndrome of autoimmune origin.
Conclusions: Systemic lupus erythematosus revealed by an activation syndrome as well as increased LV mass present two progressive indicators of cardiac morbidity and mortality requiring targeted and early treatment.
Keywords: Pericardial effusion, left ventricle hypertrophy, macrophage activation syndrome, systemic lupus erythematosus
How to Cite
Downloads
References
Tselios K., Urowitz MB Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Revues Actuelles de Rhumatologie. 2017;13(3):206–218. DOI:10.2174/1573397113666170704102444
Doherty NE, Siegel RJ Cardiovascular manifestations of systemic lupus erythematosus Journal américain du cœur. 1985;110 (6):1257–1265. DOI: 10.1016/0002-8703(85)90023-7
Usalan C, Buyukhatipoglu H, Tiryaki O. Systemic lupus erythematosus complicated by dilated cardiomyopathy and severe heart failure. Rheumatology Clinique. 2007;26(1):125– 127. DOI: 10.1007/s10067-005-0123-z
Janice Pieretti, Mary J. Roman, Richard B. Devereux et al. Systemic Lupus Erythematosus Predicts Increased Left Ventricular Mass. Circulation. 2007;116:419–426. DOI.org/10.1161/CIRCULATIONAHA.106.673319
Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322:1561–1566.
DOI: 10.1056/NEJM199005313222203.Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986; 105:173–178. DOI: 10.7326/0003-4819-105-2-173
Wong KF, Hui PK, Chan JK et al. The acute lupus hemophagocytic syndrome. Ann lntern Med. 1991;1 14: 387-90. DOI: 10.7326/0003-4819-114-5-387
Dhote R, Simon J, Papo T, et al. Reactive hemophagocytic syndrome in adult systeinic disease: report of twenty-six cases and literature review. Arthritis Rheuin. 2003;49:633-9. DOI: 10.1002/art.11368
Fukaya S, Yasuda S, Hashimoto T, et al. Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: Analysis of 30 cases. Rheumatology (Oxford). 2008;47: 1686–91. DOI: 10.1093/rheumatology/ken342